



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/920,118	07/31/2001	Rolf Menzel	10424-003	5780
7590 11/06/2003				
Pennie & Edmonds LLP 1155 Avenue of the Americas New York, NY 10036-2711			EXAMINER LEFFERS JR, GERALD G	
			ART UNIT 1636	PAPER NUMBER

DATE MAILED: 11/06/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/920,118	MENZEL, ROLF	
	Examiner	Art Unit	
	Gerald G Leffers Jr., PhD	1636	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 07 August 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-36 and 43 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-26, 28, 30, 32, 34, 36 and 43 is/are rejected.
- 7) ☒ Claim(s) 27,29,31,33 and 35 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 31 July 2001 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

Applicant's election without traverse of Group I (claims 1-36 and 43) in the paper filed 8/7/03 is acknowledged. Applicants cancelled nonelected claims in the same paper (claims 37-42 and 44). Claims 1-36 and 43 are pending in the instant application.

Sequence Compliance

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 because sequences were set forth that lack sequence identifiers, no computer readable format (CRF) was filed, no paper sequence was filed and no attorney statement was filed. These sequences include **the sequences represented in Figures 16-17**. If the Sequence Listing required for the instant application is identical to that of another application, a letter may be submitted requesting transfer of the previously filed sequence information to the instant application. For a sample letter requesting transfer of sequence information, refer to MPEP § 2422.05. Additionally, it is often convenient to identify sequences in figures by amending the Brief Description of the Drawings section (see MPEP § 2422.02). **If these sequences are in fact in the sequence listing, then applicants need only amend the Brief Description of the Drawings to include the appropriate sequence identifiers (i.e. SEQ ID NOS). If not, a new paper copy, CRF and attorney's statement concerning the sequence listing is required.**

Applicants are required to comply with all of the requirements of 37 CFR 1.821 through 1.825. Any response to this office action that fails to meet all of these requirements will be considered non-responsive. The nature of the noncompliance with the requirements of 37 C.F.R. 1.821 through 1.825 did not preclude the continued examination of the application on the merits, the results of which are communicated below.

Claim Objections

Claims 27, 29, 31, 33 and 35 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim cannot depend from a multiply dependent claim. See MPEP § 608.01(n). Accordingly, the claims have not been further treated on the merits.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-26, 28, 30, 32, 34, 36 and 43 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1 and 13 are both vague and indefinite in that the end result of the claimed method does not necessarily recapitulate the desired result recited in the preamble of the claim. The methods are directed to generation of a population of variant sequence modules, but there are no steps that clearly relate to the result of producing a population of variant sequence modules. For example, there is no clear and positive prior antecedent basis for the term

“sequence module” in the last line of the claims as the term is not explained in the course of the methods. Similarly, there is no step or element of the claim that is clearly directed to a population of sequence variants. It would be remedial to amend the claim to include the elements of 1) what constitutes a sequence module, and 2) to include elements directed to a population of sequence variants.

Claim 22 is vague and indefinite in that the metes and bounds of the term “derived from” are unclear. It is unclear the number and nature of steps required in order to generate a “derivative” of a recombination module. It would be remedial to substitute the term “obtained from” for the term “derived from” in the claim language.

Claim 43 is vague and indefinite in that the metes and bounds of the term “archived module” are unclear. The terms “module” and “archived module” do not appear to be well defined in the instant specification and are open to interpretation as to what structural compositions are encompassed by the claim. For example, would a representation of the sequence of the module archived on a computer disc be considered as an “archived module” produced by the methods of claim 1 or claim 13? Or is the term meant to specify only the physical polynucleotide structure produced by the methods? If the latter, then what are the structural ends of the polynucleotide that are comprised within the module?

Conclusion


No claims are allowed. Claims 27, 29, 31, 33 and 35 are objected to as being improperly multiply dependent and have been withdrawn from consideration.

Art Unit: 1636

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gerald G Leffers Jr., PhD whose telephone number is (703) 308-6232. The examiner can normally be reached on 9:30am-6:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel can be reached on (703) 305-1998. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.


GERRY LEFFERS
PRIMARY EXAMINER

Gerald G Leffers Jr., PhD
Primary Examiner
Art Unit 1636

Ggl